Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
4516 | 1774 | 31.7 | 72% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
8 | 4 | CARDIAC & CARDIOVASCULAR SYSTEM//PERIPHERAL VASCULAR DISEASES//CARDIOL | 1276458 |
57 | 3 | ANGIOTENSIN II//HYPERTENSION//PERIPHERAL VASCULAR DISEASES | 89232 |
85 | 2 | ANGIOTENSIN II//RENIN ANGIOTENSIN SYSTEM//ANGIOTENSIN | 27105 |
4516 | 1 | CANDESARTAN CILEXETIL//ANGIOTENSIN II RECEPTOR ANTAGONIST//LOSARTAN | 1774 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | CANDESARTAN CILEXETIL | authKW | 665009 | 5% | 47% | 82 |
2 | ANGIOTENSIN II RECEPTOR ANTAGONIST | authKW | 612670 | 7% | 29% | 122 |
3 | LOSARTAN | authKW | 395726 | 12% | 11% | 209 |
4 | FIMASARTAN | authKW | 352553 | 1% | 79% | 26 |
5 | ANGIOTENSIN II ANTAGONIST | authKW | 339384 | 3% | 35% | 56 |
6 | IRBESARTAN | authKW | 333890 | 5% | 22% | 87 |
7 | EPROSARTAN | authKW | 312883 | 2% | 45% | 40 |
8 | VALSARTAN | authKW | 185072 | 5% | 12% | 89 |
9 | AT1 RECEPTOR ANTAGONIST | authKW | 149646 | 2% | 24% | 36 |
10 | ANGIOTENSIN II RECEPTOR BLOCKER | authKW | 148948 | 4% | 12% | 71 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 9585 | 43% | 0% | 768 |
2 | Peripheral Vascular Diseases | 8543 | 21% | 0% | 368 |
3 | Chemistry, Medicinal | 4141 | 15% | 0% | 263 |
4 | Cardiac & Cardiovascular System | 1055 | 11% | 0% | 190 |
5 | Chemistry, Organic | 751 | 11% | 0% | 191 |
6 | Medicine, General & Internal | 185 | 6% | 0% | 114 |
7 | Toxicology | 85 | 3% | 0% | 51 |
8 | Medicine, Research & Experimental | 76 | 4% | 0% | 65 |
9 | Urology & Nephrology | 21 | 2% | 0% | 32 |
10 | Primary Health Care | 10 | 0% | 0% | 6 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | SMITHKLINE BEECHAM CLIN PHARMACOL UNIT | 68836 | 0% | 50% | 8 |
2 | HYPERTENS VASC MED | 63508 | 1% | 15% | 24 |
3 | KOTOBUKI S | 38723 | 0% | 75% | 3 |
4 | BIOORGAN SCI 5 | 34422 | 0% | 100% | 2 |
5 | PATHOPHYSIOL MED TEACHING | 34422 | 0% | 100% | 2 |
6 | OKLAHOMA CARDIOVASC HYPERTENS | 25029 | 0% | 36% | 4 |
7 | CARDIOL HYPERTENS UNIT | 22947 | 0% | 67% | 2 |
8 | STARNBERG HOSP | 21506 | 0% | 25% | 5 |
9 | ASAN SCI CARDIOL | 17211 | 0% | 100% | 1 |
10 | BIOCOCCA S GERARDO HOSP | 17211 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF HUMAN HYPERTENSION | 24978 | 4% | 2% | 73 |
2 | BLOOD PRESSURE | 24244 | 2% | 4% | 37 |
3 | AMERICAN JOURNAL OF HYPERTENSION | 14219 | 4% | 1% | 70 |
4 | JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM | 13201 | 1% | 3% | 26 |
5 | CLINICAL THERAPEUTICS | 8967 | 3% | 1% | 51 |
6 | JOURNAL OF HYPERTENSION | 7915 | 4% | 1% | 67 |
7 | CLINICAL DRUG INVESTIGATION | 7530 | 2% | 1% | 31 |
8 | CARDIOVASCULAR DRUG REVIEWS | 6900 | 1% | 3% | 13 |
9 | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY | 6732 | 4% | 1% | 66 |
10 | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 6182 | 5% | 0% | 96 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CANDESARTAN CILEXETIL | 665009 | 5% | 47% | 82 | Search CANDESARTAN+CILEXETIL | Search CANDESARTAN+CILEXETIL |
2 | ANGIOTENSIN II RECEPTOR ANTAGONIST | 612670 | 7% | 29% | 122 | Search ANGIOTENSIN+II+RECEPTOR+ANTAGONIST | Search ANGIOTENSIN+II+RECEPTOR+ANTAGONIST |
3 | LOSARTAN | 395726 | 12% | 11% | 209 | Search LOSARTAN | Search LOSARTAN |
4 | FIMASARTAN | 352553 | 1% | 79% | 26 | Search FIMASARTAN | Search FIMASARTAN |
5 | ANGIOTENSIN II ANTAGONIST | 339384 | 3% | 35% | 56 | Search ANGIOTENSIN+II+ANTAGONIST | Search ANGIOTENSIN+II+ANTAGONIST |
6 | IRBESARTAN | 333890 | 5% | 22% | 87 | Search IRBESARTAN | Search IRBESARTAN |
7 | EPROSARTAN | 312883 | 2% | 45% | 40 | Search EPROSARTAN | Search EPROSARTAN |
8 | VALSARTAN | 185072 | 5% | 12% | 89 | Search VALSARTAN | Search VALSARTAN |
9 | AT1 RECEPTOR ANTAGONIST | 149646 | 2% | 24% | 36 | Search AT1+RECEPTOR+ANTAGONIST | Search AT1+RECEPTOR+ANTAGONIST |
10 | ANGIOTENSIN II RECEPTOR BLOCKER | 148948 | 4% | 12% | 71 | Search ANGIOTENSIN+II+RECEPTOR+BLOCKER | Search ANGIOTENSIN+II+RECEPTOR+BLOCKER |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | NAIK, P , MURUMKAR, P , GIRIDHAR, R , YADAV, MR , (2010) ANGIOTENSIN II RECEPTOR TYPE 1 (AT(1)) SELECTIVE NONPEPTIDIC ANTAGONISTS-A PERSPECTIVE.BIOORGANIC & MEDICINAL CHEMISTRY. VOL. 18. ISSUE 24. P. 8418 -8456 | 193 | 75% | 39 |
2 | MICHEL, MC , FOSTER, C , BRUNNER, HR , LIU, LS , (2013) A SYSTEMATIC COMPARISON OF THE PROPERTIES OF CLINICALLY USED ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONISTS.PHARMACOLOGICAL REVIEWS. VOL. 65. ISSUE 2. P. 809-848 | 191 | 42% | 64 |
3 | WEXLER, RR , GREENLEE, WJ , IRVIN, JD , GOLDBERG, MR , PRENDERGAST, K , SMITH, RD , TIMMERMANS, PBMWM , (1996) NONPEPTIDE ANGIOTENSIN II RECEPTOR ANTAGONISTS: THE NEXT GENERATION IN ANTIHYPERTENSIVE THERAPY.JOURNAL OF MEDICINAL CHEMISTRY. VOL. 39. ISSUE 3. P. 625 -656 | 139 | 70% | 242 |
4 | ISRAILI, ZH , (2000) CLINICAL PHARMACOKINETICS OF ANGIOTENSIN II (AT(1)) RECEPTOR BLOCKERS IN HYPERTENSION.JOURNAL OF HUMAN HYPERTENSION. VOL. 14. ISSUE . P. S73 -S86 | 79 | 78% | 126 |
5 | DINA, R , JAFARI, M , (2000) ANGIOTENSIN II-RECEPTOR ANTAGONISTS: AN OVERVIEW.AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY. VOL. 57. ISSUE 13. P. 1231 -1241 | 58 | 87% | 38 |
6 | YANG, RR , LUO, ZQ , LIU, Y , SUN, M , ZHENG, L , CHEN, YY , LI, YP , WANG, H , CHEN, LZ , WU, M , ET AL (2016) DRUG INTERACTIONS WITH ANGIOTENSIN RECEPTOR BLOCKERS: ROLE OF HUMAN CYTOCHROMES P450.CURRENT DRUG METABOLISM. VOL. 17. ISSUE 7. P. 681 -691 | 54 | 63% | 0 |
7 | CONLIN, PR , SPENCE, JD , WILLIAMS, B , RIBEIRO, AB , SAITO, I , BENEDICT, C , BUNT, AMG , (2000) ANGIOTENSIN II ANTAGONISTS FOR HYPERTENSION: ARE THERE DIFFERENCES IN EFFICACY?.AMERICAN JOURNAL OF HYPERTENSION. VOL. 13. ISSUE 4. P. 418 -426 | 42 | 91% | 108 |
8 | SICA, DA , GEHR, TWB , GHOSH, S , (2005) CLINICAL PHARMACOKINETICS OF LOSARTAN.CLINICAL PHARMACOKINETICS. VOL. 44. ISSUE 8. P. 797-814 | 59 | 59% | 54 |
9 | CSAJKA, C , BUCLIN, T , BRUNNER, HR , BIOLLAZ, J , (1997) PHARMACOKINETIC-PHARMACODYNAMIC PROFILE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS.CLINICAL PHARMACOKINETICS. VOL. 32. ISSUE 1. P. 1-29 | 56 | 78% | 58 |
10 | HERAN, BS , WONG, MMY , HERAN, IK , WRIGHT, JM , (2008) BLOOD PRESSURE LOWERING EFFICACY OF ANGIOTENSIN RECEPTOR BLOCKERS FOR PRIMARY HYPERTENSION.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 4. P. - | 43 | 69% | 23 |
Classes with closest relation at Level 1 |